The reproductive implications of GLP-1 receptor agonists in metabolically healthy, non-PCOS women are mostly unexamined, and preclinical evidence suggests possible safety issues in certain scenarios. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.